LCTX:NYE-Lineage Cell Therapeutics Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 1

Change

-0.01 (-0.99)%

Market Cap

USD 0.19B

Volume

0.45M

Analyst Target

USD 4.80
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NVO Novo Nordisk A/S

-1.73 (-1.27%)

USD 612.29B
BHVN Biohaven Pharmaceutical Holdin..

-0.32 (-0.84%)

USD 3.61B
RCUS Arcus Biosciences Inc

-0.25 (-1.51%)

USD 1.58B
NUVB Nuvation Bio Inc

+0.03 (+1.01%)

USD 0.80B
DNA Ginkgo Bioworks Holdings

+0.14 (+2.30%)

USD 0.39B
ADCT ADC Therapeutics SA

+0.05 (+1.83%)

USD 0.27B
CYBN Cybin Inc

-0.01 (-3.03%)

USD 0.20B
ANVS Annovis Bio Inc

+0.06 (+0.72%)

USD 0.11B
ARMP Armata Pharmaceuticals Inc

+0.08 (+3.13%)

USD 0.09B
MAIA MAIA Biotechnology Inc.

+0.46 (+15.75%)

USD 0.07B

ETFs Containing LCTX

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -8.26% 53% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.26% 53% F 15% F
Trailing 12 Months  
Capital Gain -29.58% 39% F 8% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -29.58% 39% F 8% B-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 28.11% 84% B 89% A-
Dividend Return 28.11% 84% B 88% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 85.16% 39% F 9% A-
Risk Adjusted Return 33.01% 84% B 54% F
Market Capitalization 0.19B 71% C- 32% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.